AcelRx Pharmaceuticals Inc reports results for the quarter ended in December - Earnings Summary

Talphera

30/03/2023 22:02

* AcelRx Pharmaceuticals Inc  ACRX.OQ  reported a quarterly
adjusted loss of 100 cents​​ per share for the quarter ended in
December. The mean expectation of two analysts for the quarter
was for a loss of 51 cents per share.
    * Revenue rose 12,500% to $252.00 thousand from a year ago;
analysts expected $4.50 million. 
    * AcelRx Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of $1.00​.
    * The mean earnings estimate of analysts was unchanged in
the last
three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company. 
    * AcelRx Pharmaceuticals Inc shares had fallen by 68.1% this
quarter.
    * The company reported a quarterly loss of $7.48 million.
    * Wall Street's median 12-month price target for AcelRx
Pharmaceuticals Inc is $80.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 1 "strong buy" or "buy," 1
"hold" and no "sell" or "strong sell." 

This summary was machine generated from LSEG Refinitiv data
March 30 at 09:02 p.m. UTC. ​All figures in US dollars unless
otherwise stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Dec. 31 2022      -0.51          -1.00          Missed
 Sep. 30 2022      -1.20          -0.94          Beat
 Jun. 30 2022      -1.50          -1.20          Beat
 Mar. 31 2022      -1.20          -1.20          Met